$1,369.25
Value $1.29T
LLY and WST stock compared: price, dividend, valuation and results, from SEC filings.
$1,369.25
Value $1.29T
$396.81
Value $28.6B
Eli Lilly and Company (LLY) has a market value of $1.29T and West Pharmaceutical Services (WST) $28.6B. Over the last year, with dividends, LLY moved +33.1% and WST +53.0%. The P/E is 46.8 for LLY and 44.7 for WST. Dividend yield: LLY 0.46%, WST 0.23%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LLY$1.29T
WST$28.6B
LLY is 45 times WST
Revenue, 12 months
LLY$86.5B
WST$3.4B
LLY is 25 times WST
Net income, 12 months
LLY$27.6B
WST$639M
LLY is 43 times WST
Operating margin
LLY–
WST23.0%
ROIC
LLY35.5%
WST19.0%
16.5 points apart
P/E
LLY46.8
WST44.7
About the same
Dividend yield
LLY0.5%
WST0.2%
0.3 points apart
5-year return
LLY+444.6%
WST-10.5%
455.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LLY+444.6%
WST-10.5%
| Period | LLYWith dividends | WSTWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +33.1%Price +32.3% | +53.0%Price +52.5% |
| 3 years since November 17, 2023 | +135.0%+33.0% a yearPrice +130.4% | +16.8%+5.3% a yearPrice +15.8% |
| 5 years since November 18, 2021 | +444.6%+40.4% a yearPrice +421.6% | -10.5%-2.2% a yearPrice -11.7% |
| 10 years since November 21, 2016 | +1,969.0%+35.4% a yearPrice +1,678.7% | +411.9%+17.7% a yearPrice +394.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LLYEli Lilly and CompanyWSTWest Pharmaceutical Services
| Price | $1,369.25 | $396.81 |
|---|---|---|
| Market value | $1.29T | $28.6B |
| Enterprise value (EV) | $1.34T | $28.3B |
| P/E | 46.8 | 44.7 |
| P/E, 5-year median | 49.9 | 44.7 |
| P/B | 32.1 | 9.6 |
| EV/EBIT | 38.4 | 36.3 |
| Free cash flow yield | 1.5% | 1.6% |
| Revenue, 12 months | $86.5B | $3.4B |
|---|---|---|
| Net income, 12 months | $27.6B | $639M |
| Free cash flow, 12 months | $19.7B | $453M |
| Earnings per share, 12 months | $30.81 | $8.91 |
| Revenue growth, year on year | 44.7% | 6.3% |
| Revenue growth a year, past | +21.6%over 5 years | +7.4%over 5 years |
| EPS growth a year, past | +27.6%over 5 years | +8.2%over 5 years |
| Gross margin | 83.6% | 37.6% |
|---|---|---|
| Operating margin | – | 23.0% |
| Net margin | 31.9% | 18.8% |
| ROIC | 35.5% | 19.0% |
| ROE | 88.6% | 21.1% |
| Cash | $4.9B | $464M |
|---|---|---|
| Total debt | $49.5B | $314M |
| Net debt / EBITDA | 1.2 | -0.3 |
| Interest cover | 38.9× | 96.3× |
| Dividend yield | 0.5% | 0.2% |
|---|---|---|
| Dividend per share, 12 months | $6.34 | $0.92 |
| Dividend growth a year, past | +15.2%over 5 years | +5.4%over 5 years |
| Buyback yield | 0.3% | 0.5% |
| Shareholder yield | 0.8% | 0.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.29T) is about 45.2 times West Pharmaceutical Services ($28.6B), at today's prices.
Since November 21, 2016, LLY's price moved +1,678.7% and WST's +394.1%. With dividends: LLY +1,969.0% (+35.4% a year), WST +411.9% (+17.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.46% for Eli Lilly and Company and 0.23% for West Pharmaceutical Services. Over the last twelve months they paid $6.34 and $0.92 per share.
At today's price, the P/E is 46.8 for LLY and 44.7 for WST. The median of the last five years was 49.9 and 44.7, which shows where each stands against its own past.
Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and 18.8% for West Pharmaceutical Services, and the operating margin – and 23.0%. Revenue was $86.5B and $3.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.